Introduction {#sec1}
============

Currently, coronary artery disease (CAD) is one of the leading cause of deaths worldwide \[[@B1],[@B2]\]. The 2017 China Reports of Cardiovascular Diseases showed that the prevalence of CAD disease in China is still on the rise \[[@B3]\]. In next decades, CAD is expected to cause approximately 3.4 million deaths in China.

Multiple risk factors contribute to CAD development \[[@B4],[@B5]\]. Recently, genome-wide association study (GWAS) has revealed single nucleotide polymorphism genes (SNPs) which are related with CAD risk. As genetic inheritance is an inevitable risk factor in the development of CAD, it is critical to identify the SNP locus of CAD risk \[[@B4],[@B6]\].

Long non-coding RNA (lncRNA) is one of the most important members of non-coding RNA family. Recently, numerous studies have reported that lncRNA plays a regulatory role in other complex diseases, such as cancer, ischemic stroke, Alzheimer's disease, and heart disease \[[@B9]\].

Particularly, MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) known as non-coding nuclear-enriched abundant transcript 2 (NEAT2) is the one of the first found lncRNA with widely expression in various mammalian species \[[@B14]\]. MALAT1 is located on chromosome 11q13.1, majorly expressed in nucleus and is highly conserved. Moreover, it has high expression in various human tissues \[[@B15]\].

Many studies have shown that lncRNA MALAT1 was associated with CAD risk \[[@B19]\]. In 2012, Zhuo et al. \[[@B19]\] demonstrated that rs619586A→G regulated the expression of XBP1, and ultimately prevented the proliferation and metastasis of pulmonary artery endothelial cells. Vausort et al. \[[@B40]\] found that MALAT1 levels in peripheral blood cells was significantly higher in acute myocardial infarction patients compared with controls. Wang et al. \[[@B20]\] found that MALAT1 SNP rs619586 AG/GG genotypes may protect against the occurrence of CAD, but not rs11227209, rs664589, and rs3200401. To our knowledge, no evidence demonstrates the relationship between MALAT1 SNP and CAD risk. In addition, we further conducted SNP--SNP and SNP--environmental factors interaction analysis \[[@B20]\].

In summary, we conducted a case--control study, analyzed statistical methods with clinical data, and detected relationship between MALAT1 (rs619586, rs4102217) SNPs and CAD risk. The aim of the present study was to identify predictive biomarkers for CAD risk and establish an experimental basis to improve understanding of the etiology and the mechanism of CAD.

Materials and methods {#sec2}
=====================

Patients {#sec2-1}
--------

The Ethical Committee of the Fourth Affiliated Hospital of the China Medical University approved this research project and written informed consent was obtained. All clinical investigations have been conducted according to the principles described in the Declaration of Helsinki. A total of 749 participants were recruited in the present study, including 365 CAD patients and 384 matched controls. All diagnoses were made based on 2014 AHA/ACC guidelines for the management of NSTEACS and Third Universal Definition of Myocardial Infarction, with confirmation by coronary angiography \[[@B21]\]. Coronary artery and Gensini score assessed the severity of CAD \[[@B22],[@B23]\]. A total of 384 gender and age frequency-matched controls were included from a health screening program from the community of the same area, Liaoning Province, China from 2012 to 2014. Peripheral venous blood specimens were collected from participants and stored at −20°C until use.

Exclusion criteria included history of malignancies, rheumatoid arthritis, and connective tissue diseases, organ transplantation, and long-term use of immunosuppressive medication.

SNP selection and genotyping {#sec2-2}
----------------------------

Genetic polymorphisms were screened by HapMap database. Haploview 4.2 was used to select, and according to Chinese Beijing Han population (CHB), unbalanced R2 value more than 0.8, and the minimum allele frequency (Minor Allele Frequency, MAF) was greater than 5%. F-SNP software (<http://compbio.cs.queensu.ca/F-SNP/>) was used to predict the possible functions of these selected sites. At last, we selected MALAT1 tagSNPs according to the literature \[[@B24]\]. The most common SNPs on *MALAT1* gene were two sites (rs4102217, rs619586).

Genomic DNA was extracted using a previously published method and diluted to working concentrations of 20 ng.l^−1^ for genotyping. The assay was performed by Gene Company (Shanghai, China), using allele-specific PCR using KASPar (KASP) reagents (LGC Genomics, Hoddesdon, U.K.). For quality control, we repeatedly genotyped 10% of the total samples at one time. The concordance rate of these repeated samples reached 100%, which demonstrated that the genotyping results were reliable.

Statistical analysis {#sec2-3}
--------------------

Between-group differences of gender as well as the Hardy--Weinberg Equilibrium were compared by the χ^2^ test, and ANOVA was conducted for age variability. Multivariate logistic regression with adjustments for age and gender was used to show the association between selected gene polymorphisms with CAD risk. The haplotype of each gene was analyzed using SHEsis software \[[@B25],[@B26]\]. All MALAT1 gene polymorphisms identified in the best models of gene--gene interactions were calculated using MDR software (version 3.0.2). The combined effect of selected SNP--SNP interactions in the best model was determined by multivariate logistic regression adjusted for age and gender. The association between gene polymorphisms and clinical parameters was performed by χ^2^ test; the differences for the clinical parameters amongst different polymorphism groups were compared by using *t* test. *P*-value \<0.05 was considered significant.

Results {#sec3}
=======

The baseline characteristics of the subjects {#sec3-1}
--------------------------------------------

The demographic characteristics of CAD and control subjects were shown in Supplementary Table S1. There was no significant difference in the age (57.0 ± 8.1 compared with 57.4 ± 8.8 years) and gender (male 73.7% compared with female 75.6%) between the CAD and control groups. There were remarkable differences in the two groups of CAD risk factors, including smoking, drinking, hypertension, diabetes, cerebrovascular disease, total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein (*P*\<0.05).

The association of SNPs in *MALAT1* gene with CAD risk {#sec3-2}
------------------------------------------------------

We genotyped two polymorphisms of lncRNA MALAT1 gene (rs619586 and rs4102217) ([Table 1](#T1){ref-type="table"}). The two SNPs were conformed to the Hardy--Weinberg Equilibrium. However, we did not find any relationship between the two SNPs and CAD risk (*P*\>0.05).

###### The association of lncRNA MALAT1 polymorphisms and CAD risk^1^

  SNPs                     CON (%)      CAD (%)      CAD compared with CON   
  ------------------------ ------------ ------------ ----------------------- -------------------
  MALAT1 rs4102217                                                           
  GG                       275 (77.9)   243 (72.1)                           1 (Ref)
  GC                       78 (22.1)    94 (27.9)    0.076                   1.37 (0.97--1.94)
  CC                       11 (3.8)     8 (3.2)      0.705                   0.84 (0.33--2.12)
  CC+GC compared with GG                             0.120                   1.30 (0.93--1.82)
  CC compared with GC+GG                             0.575                   0.77 (0.31--1.93)
  C compared with G                                  0.233                   1.20 (0.89--1.60)
  *P*~HWE~^2^              0.068                                             
  MALAT1 rs619586                                                            
  AA                       309 (87.0)   293 (85.4)                           1 (Ref)
  AG                       46 (13.0)    50 (14.6)    0.531                   1.15 (0.75--1.77)
  GG                       2 (0.6)      1 (0.3)      0.667                   0.59 (0.05--6.56)
  GG+AG compared with AA                             0.589                   1.13 (0.74--1.72)
  GG compared with G+AA                              0.628                   0.55 (0.05--6.12)
  G compared with A                                  0.671                   1.09 (0.73--1.63)
  *P*~HWE~^2^              0.839                                             

Abbreviations: CI, confidence interval; CON, control, OR, odds ratio; NCBI Ref, the reference frequencies of these polymorphisms in Beijing Han, China in NCBI database.

^1^Using logistic regression adjusted by sex and age.

^2^Means Hardy−Weinberg Equilibrium in population.

The association of MALAT1 polymorphisms with CAD risk stratified by individual characteristics {#sec3-3}
----------------------------------------------------------------------------------------------

To minimize other CAD risk factors influences, we carried out a stratified analysis ([Table 2](#T2){ref-type="table"}). The GC genotype and the recessive model of rs4102217 polymorphism showed stronger relations with higher CAD risk both in non-drinkers (*P*=0.010, odds ratio (OR): 1.96, 95% confidence interval (CI) = 1.17--3.28; *P*=0.026, OR: 1.73, 95% CI = 1.07--2.79, respectively) and in diabetes mellitus (DM) history group (*P*=0.010, OR: 4.07, 95% CI = 1.41--11.81; *P*=0.019, OR: 3.29, 95% CI = 1.22--8.88, respectively). We did not observe any changes in rs619586 (*P*\>0.05).

###### The association of lncRNA MALAT1 polymorphisms and CAD risk stratified by host characteristics

  Variables          Genotype                 CAD compared with CON   *P*^1^      OR (95% CI)
  ------------------ ------------------------ ----------------------- ----------- ------------------------
  MALAT1 rs4102217                                                                
  Gender                                                                          
    Male             GG                       189/201                             1 (Ref)
                     GC                       65/58                   0.319       1.23 (0.82--1.84)
                     CC                       6/7                     0.871       0.91 (0.30--2.76)
                     CC+GC compared with GG                           0.372       1.19 (0.81--1.76)
                     CC compared with GC+GG                           0.799       0.87 (0.29--2.61)
    Female           GG                       54/74                               1 (Ref)
                     GC                       27/20                   0.072       1.86 (0.95--3.68)
                     CC                       2/4                     0.696       0.71 (0.12--4.03)
                     CC+GC compared with GG                           0.121       1.67 (0.87--3.18)
                     CC compared with GC+GG                           0.545       0.59 (0.11--3.30)
  Age (years)                                                                     
    ≤60              GG                       149/162                             1 (Ref)
                     GC                       53/44                   0.251       1.31 (0.83--2.07)
                     CC                       8/6                     0.487       1.47 (0.50--4.37)
                     CC+GC compared with GG                           0.198       1.33 (0.86--2.06)
                     CC compared with GC+GG                           0.529       1.42 (0.48--4.18)
    \>60             GG                       94/113                              1 (Ref)
                     GC                       41/34                   0.164       1.47 (0.86--2.53)
                     CC                       0/5                     NA          NA
                     CC+GC compared with GG                           0.361       1.28 (0.76--2.17)
                     CC compared with GC+GG                           NA          NA
  Smoking                                                                         
    Ever smoker      GG                       168/144                             1 (Ref)
                     GC                       58/63                   0.298       1.28 (0.80--2.04)
                     CC                       7/4                     0.568       1.45 (0.41--5.11)
                     CC+GC compared with GG                           0.257       1.30 (0.83--2.03)
                     CC compared with GC+GG                           0.627       1.37 (0.39--4.80)
    Never smoker     GG                       75/131                              1 (Ref)
                     GC                       36/39                   0.080       1.62 (0.94--2.77)
                     CC                       1/7                     0.185       0.24 (0.03--1.99)
                     CC+GC compared with GG                           0.205       1.40 (0.83--2.36)
                     CC compared with GC+GG                           0.146       0.21 (0.03--1.72)
  Alcohol drinking                                                                
    Drinker          GG                       65/151                              1 (Ref)
                     GC                       24/50                   0.780       1.09 (0.61--1.92)
                     CC                       2/5                     0.909       1.11 (0.20--6.20)
                     CC+GC compared with GG                           0.787       1.08 (0.62--1.88)
                     CC compared with GC+GG                           0.986       1.02 (0.19--5.49)
    Non-drinker      GG                       178/124                             1 (Ref)
                     GC                       70/28                   **0.010**   **1.96 (1.17--3.28)**
                     CC                       6/6                     0.557       0.70 (0.21--2.30)
                     CC+GC compared with GG                           **0.026**   **1.73 (1.07--2.79)**
                     CC compared with GC+GG                           0.396       0.60 (0.18--1.96)
  HBP                                                                             
    Yes              GG                       135/89                              1 (Ref)
                     GC                       54/23                   0.168       1.48 (0.85--2.60)
                     CC                       4/2                     0.945       1.07 (0.18--6.23)
                     CC+GC compared with GG                           0.173       1.46 (0.85--2.52)
                     CC compared with GC+GG                           0.941       1.07 (0.19--6.05)
    NO               GG                       107/186                             1 (Ref)
                     GC                       40/55                   0.383       1.24 (0.77--2.00)
                     CC                       4/9                     0.647       0.75 (0.22--2.57)
                     CC+GC compared with GG                           0.498       1.17 (0.74--1.85)
                     CC compared with GC+GG                           0.611       0.73 (0.22--2.45)
  DM                                                                              
    Yes              GG                       62/39                               1 (Ref)
                     GC                       29/5                    **0.010**   **4.07 (1.41--11.81)**
                     CC                       0/1                     NA          NA
                     CC+GC compared with GG                           **0.019**   **3.29 (1.22-8.88)**
                     CC compared with GC+GG                           NA          NA
    No               GG                       181/235                             1 (Ref)
                     GC                       65/73                   0.412       1.18 (0.80--1.74)
                     CC                       8/10                    0.884       1.07 (0.41--2.81)
                     CC+GC compared with GG                           0.426       1.16 (0.80--1.69)
                     CC compared with GC+GG                           0.963       1.02 (0.40--2.65)
  LDL                                                                             
    High             GG                       44/56                               1 (Ref)
                     GC                       14/16                   0.787       1.12 (0.49--2.59)
                     CC                       2/2                     0.801       1.29 (0.18--9.59)
                     CC+GC compared with GG                           0.732       1.15 (0.52--2.54)
                     CC compared with GC+GG                           0.819       1.26 (0.17--9.26)
    Normal           GG                       174/211                             1 (Ref)
                     GC                       65/60                   0.183       1.32 (0.88--1.98)
                     CC                       5/9                     0.489       0.68 (0.22--2.06)
                     CC+GC compared with GG                           0.293       1.23 (0.83--1.82)
                     CC compared with GC+GG                           0.414       0.63 (0.21--1.91)
    Low              GG                       12/6                                1 (Ref)
                     GC                       8/2                     0.564       1.84 (0.23--14.68)
                     CC                       0/0                     NA          NA
                     CC+GC compared with GG                           0.564       1.84 (0.23--14.68)
                     CC compared with GC+GG                           NA          NA
  MALAT1 rs619586                                                                 
  Gender                                                                          
    Male             AA                       225/223                             1 (Ref)
                     AG                       33/36                   0.699       0.91 (0.54--1.50)
                     GG                       1/1                     0.923       1.15 (0.07--18.62)
                     GG+AG compared with AA                           0.709       0.91 (0.55--1.50)
                     GG compared with AG+AA                           0.956       1.08 (0.07-17.50)
    Female           AA                       68/86                               1 (Ref)
                     AG                       17/10                   0.069       2.19 (0.94--5.11)
                     GG                       0/1                     NA          NA
                     GG+AG compared with AA                           0.103       1.99 (0.87--4.53)
                     GG compared with AG+AA                           NA          NA
  Age (years)                                                                     
    ≤60              AA                       175/184                             1 (Ref)
                     AG                       29/25                   0.487       1.23 (0.69--2.18)
                     GG                       1/1                     0.993       1.01 (0.06--16.35)
                     GG+AG compared with AA                           0.493       1.22 (0.69--2.15)
                     GG compared with AG+AA                           0.990       1.02 (0.06--16.40)
    \>60             AA                       118/125                             1 (Ref)
                     AG                       21/21                   0.898       1.04 (0.54--2.01)
                     GG                       0/1                     NA          NA
                     GG+AG compared withAA                            0.995       1.00 (0.52--1.91)
                     GG compared with AG+AA                           NA          NA
  Smoking                                                                         
    Ever smoker      AA                       205/159                             1 (Ref)
                     AG                       30/24                   0.983       0.99 (0.56--1.77)
                     GG                       1/1                     0.949       0.91 (0.06--14.86)
                     GG+AG compared with AA                           0.970       0.99 (0.56--1.75)
                     GG compared with AG+AA                           0.928       0.88 (0.05--14.28)
    Never smoker     AA                       88/150                              1 (Ref)
                     AG                       20/22                   0.186       1.57 (0.81--3.05)
                     GG                       0/1                     NA          NA
                     GG+AG compared with AA                           0.235       1.49 (0.77--2.89)
                     GG compared with AG+AA                           NA          NA
  Alcohol drinking                                                                
    Drinker          AA                       78/174                              1 (Ref)
                     AG                       13/26                   0.800       1.10 (0.53--2.26)
                     GG                       0/1                     NA          NA
                     GG+AG compared with AA                           0.884       1.06 (0.52--2.16)
                     GG compared with AG+AA                           NA          NA
    Non-drinker      AA                       215/135                             1 (Ref)
                     AG                       37/20                   0.481       1.24 (0.68--2.27)
                     GG                       1/1                     0.834       0.74 (0.04--12.70)
                     GG+AG compared with AA                           0.515       1.22 (0.67--2.20)
                     GG compared with AG+AA                           0.800       0.69 (0.04--11.75)
  HBP                                                                             
    Yes              AA                       165/90                              1 (Ref)
                     AG                       31/16                   0.957       1.02 (0.53--1.98)
                     GG                       0/2                     NA          NA
                     GG+AG compared with AA                           0.758       0.90 (0.48--1.72)
                     GG compared with AG+AA                           NA          NA
    No               AA                       127/219                             1 (Ref)
                     AG                       19/30                   0.814       1.08 (0.58--2.01)
                     GG                       1/0                     NA          NA
                     GG+AG compared with AA                           0.695       1.13 (0.61--2.09)
                     GG compared with AG+AA                           NA          NA
  DM                                                                              
    Yes              AA                       71/39                               1 (Ref)
                     AG                       17/7                    0.778       1.15 (0.43--3.12)
                     GG                       0/0                     NA          NA
                     GG+AG compared with AA                           0.778       1.15 (0.43--3.12)
                     GG compared with AG+AA                           NA          NA
    No               AA                       222/269                             1 (Ref)
                     AG                       33/39                   0.997       1.00 (0.61--1.65)
                     GG                       1/2                     0.802       0.73 (0.07--8.22)
                     GG+AG compared with AA                           0.959       0.99 (0.60--1.61)
                     GG compared with AG+AA                           0.768       0.70 (0.06--7.78)
  LDL                                                                             
    High             AA                       56/54                               
                     AG                       6/15                    0.065       0.38 (0.14--1.06)
                     GG                       1/1                     0.936       0.89 (0.05--14.86)
                     GG+AG compared with AA                           0.072       0.41 (0.16--1.08)
                     GG compared with AG+AA                           1.000       1.00 (0.06--16.55)
    Normal           AA                       204/246                             
                     AG                       36/29                   0.128       1.50 (0.89--2.54)
                     GG                       0/1                     NA          NA
                     GG+AG compared with AA                           0.159       1.46 (0.86--2.45)
                     GG compared with AG+AA                           NA          NA
    Low              AA                       16/6                                
                     AG                       4/2                     0.782       0.74 (0.09--8.37)
                     GG                       0/0                     NA          NA
                     GG+AG compared with AA                           0.782       0.74 (0.09--6.37)
                     GG compared with AG+AA                           NA          NA

Abbreviations: CON, control; HBP, high blood pressure; LDL, low-density lipoprotein.

^1^Using Logistic Regression adjusted by gender and age.

Values in bold represent statistical significance.

The association between haplotype of MALAT1 SNPs and CAD risk {#sec3-4}
-------------------------------------------------------------

Haplotypes with a frequency less than 0.03 would be excluded from our analysis ([Table 3](#T3){ref-type="table"}). There were no significant differences in the haplotype analysis (*P*\>0.05).

###### The association of haplotype of *MALAT1* gene and CAD risk

  Haplotype   Case (%)         Control (%)      *P*     OR (95% CI)
  ----------- ---------------- ---------------- ------- -------------------
  CA          88.83 (0.135)    97.97 (0.141)    0.838   0.97 (0.71--1.32)
  GA          520.17 (0.788)   549.03 (0.789)   0.560   1.08 (0.83--1.41)
  GG          39.83 (0.060)    48.97 (0.070)    0.508   0.86 (0.56--1.33)

Used SHEsis software for analysis (<http://analysis.bio-x.cn/>).

Multidimensional analysis of SNP--SNP interactions between MALAT1 and CAD risk {#sec3-5}
------------------------------------------------------------------------------

To investigate SNP--SNP interactions between MALAT1 and CAD risk, multiple logistic regression analysis was employed ([Table 4](#T4){ref-type="table"}). We found rs4102217 had interactions with smokers (GG: OR: 2.04, 95% CI = 1.42--2.92; CC+GC: OR: 2.64, 95% CI = 1.64--4.26) and drinkers (CC+GC: OR: 0.33, 95% CI = 0.20--0.55). We also found MALAT1 rs619586 AA genotype (OR: 2.20, 95% CI = 1.57--3.07) and GG+AG genotype (OR: 2.11, 95% CI = 1.17--3.81) had higher risks of CAD in smokers. In addition, rs619586 AA genotype (OR: 0.22, 95% CI = 0.10--0.48) and GG+AG genotype (OR: 0.38, 95% CI = 0.22--0.65) had lower risks of CAD in drinkers. Meanwhile, MDR software was used to further investigate the locus--locus interactions of MALAT1 and CAD risk ([Table 5](#T5){ref-type="table"}). We found that the three factors model, MALAT1 rs4102217 polymorphism-smoking-drinking was the best interaction model. The maximum testing accuracy was 0.6979, the maximum CV consistency was 10/10. Furthermore, we conducted cumulative effect of the interacting factors of MALAT1 SNPs on CAD risk ([Table 6](#T6){ref-type="table"}). MALAT1 rs4102217 polymorphism-smoking-drinking was considered as an integrated risk factor. CAD patients were divided into five groups of risks: group 1:0 risk genotype; group 2: 1 risk genotype; group 3: 2 risk genotypes; group 4: 3 risk genotypes; and group 5: 4 risk genotypes. After adjustment of gender and age, group 2 had a higher risk of CAD (*P*=0.009, OR: 1.84, 95% CI = 1.17--2.90).

###### The interaction of three MALAT1 polymorphisms with environmental factors in CAD risk

                                    Smoking                          Drinking                                              
  ------------------ -------------- -------------------------------- --------------------------------- ------------------- --------------------
  MALAT1 rs4102217                                                                                                         
  GG                 Case/control   75/131                           168/144                           178/124             65/151
                     OR (95% CI)    1 (Ref)                          2.04 (1.42--2.92)                 1 (Ref)             0.30 (0.21---0.43)
  CC+GC              Case/control   37/46                            65/43                             76/34               26/55
                     OR (95% CI)    1.41 (0.84--2.36)                2.64 (1.64--4.26)                 1.56 (0.98--2.48)   0.33 (0.20--0.55)
                                    *P*~interaction~=0.825           *P*~interaction~=0.207                                
                                    OR = 0.93, 95% CI = 0.47--1.84   OR = 0.624, 95% CI = 0.30--1.30                       
  MALAT1 rs619586                                                                                                          
  AA                 Case/control   88/150                           205/19                            215/135             78/174
                     OR (95% CI)    1 (Ref)                          2.20 (1.57--3.07)                 1 (Ref)             0.22 (0.10--0.48)
  GG+AG              Case/control   20/23                            31/25                             38/21               13/27
                     OR (95% CI)    1.48 (0.77--2.85)                2.11 (1.17--3.81)                 1.41 (0.84--2.37)   0.38 (0.22--0.65)
                                    *P*~interaction~=0.355           *P*~interaction~=0.753                                
                                    OR = 0.66, 95% CI = 0.28--1.58   OR = 0.86, 95% CI = 0.34--2.18                        

*P* for interaction used logistic regession adjusted by gender, age.

###### Gene--gene interaction models for MALAT1 two polymorphisms for CAD risk by MDR analysis

  Model                                               Training Bal. Acc.   Testing Bal. Acc.   Sign Test (*P*)   CV Consistency   *P* for permutation test
  --------------------------------------------------- -------------------- ------------------- ----------------- ---------------- --------------------------
  Drinking                                            0.6598               0.6601              10 (0.0010)       10/10            0.0000--0.0010
  Smoking-Drinking                                    0.6790               0.6789              10 (0.0010)       10/10            0.0000--0.0010
  MALAT1 rs4102217-smoking-drinking^1^                0.6995               0.6979              10 (0.0010)       10/10            0.0000--0.0010
  MALAT1 rs4102217-MALAT1 rs619586-smoking-drinking   0.7054               0.6900              10 (0.0010)       10/10            0.0000--0.0010

The best model was selected as the one with the maximum testing accuracy and maximum CV consistency.

^1^In this study, the best interaction model was the three-factor model including MALAT1 rs4102217 polymorphism-smoking-drinking.

###### Cumulative effect of the interacting factors of MALAT1 SNPs on CAD

  Number of interacting genotypes                        Total population               
  ------------------------------------------------------ ------------------ ----------- -----------------------
  MALAT1 rs41022173-rsMALAT1 rs619568-smoking-drinking                                  
  0                                                      56/75                          1 (Ref)
  1                                                      134/92             **0.009**   **1.84 (1.17--2.90)**
  2                                                      105/127            0.904       0.97 (0.60--1.58)
  3                                                      31/51              0.266       0.70 (0.38--1.31)
  4                                                      4/3                0.610       1.50 (0.32--7.13)
                                                         *P*~trend~=0.198               

^1^, Adjusted by sex and age.

Values in bold represent statistical significance.

The association between MALAT1 polymorphisms and clinical parameters {#sec3-6}
--------------------------------------------------------------------

To analyze the relationship between clinical parameters and genetic polymorphisms, the main genetic polymorphisms model was selected. In general, if the *P*-value of the dominant model was less than the recessive model, then the dominant model was selected, otherwise the recessive model was selected ([Table 7](#T7){ref-type="table"}). In our data, the dominant gene model was selected both in MALAT1 rs4102217 and in MALAT1 rs619586. We found that MALAT1 rs4102217 CC+GC genotype was higher in uric acid in both qualitative analysis (*P*=0.014) and quantitative analysis (359.35 ± 109.90 compared with 327.06 ± 115.38 μmol/l; *P*=0.015). Moreover, we found that the wild-type triglyceride for MALAT1 rs619586 was lower than the mutation (*P*=0.003), and the content was significantly lower (1.82 ± 1.39 compared with 3.12 ± 3.58 mmol/l; *P*=0.017). High-density lipoprotein in wild-type is significantly higher than mutation-type for MALAT1 rs619586 (1.02 ± 0.29 compared with 0.92 ± 0.24 mmol/l, *P*=0.032). There was a dramatic increase in uric acid in the wild-type than in the mutation-type (342.75 ± 101.42 compared with 385.04 ± 159.87 μmol/l, *P*=0.013). In addition, we analyzed the association of MALAT1 SNPs with severity of coronary artery by analyzing numbers of coronary artery lesion branches and Gensini score. But there was no statistical significance (*P*\>0.05).

###### The association of MALAT1 SNPs and clinical features

  Variation                  Wild-type       Mutated-type      Wild-type         Mutated-type    *P*
  -------------------------- --------------- ----------------- ----------------- --------------- -------
  **MALAT1 rs4102217**                                                                           
  Smoking                    *P*=0.327                                                           
    No                       75 (30.9)       37 (36.3)         /                 /               /
    Yes                      168 (69.1)      65 (63.7)         /                 /               /
  Drinking                   *P*=0.809                                                           
    No                       178 (73.3)      76 (74.5)         /                 /               /
    Yes                      65 (26.7)       26 (25.5)         /                 /               /
  HBP                        *P*=0.854                                                           
    No                       107 (44.2)      44 (43.1)         /                 /               /
    Yes                      135 (55.8)      58 (56.9)         /                 /               /
  Diabetes                   *P*=0.575                                                           
    No                       181 (74.5)      73 (71.6)         /                 /               /
    Yes                      62 (25.5)       29 (28.4)         /                 /               /
  Cerebrovascular disease    *P*=0.570                                                           
    No                       208 (86.0)      90 (88.2)         /                 /               /
    Yes                      34 (14.0)       12 (11.8)         /                 /               /
  Hyperlipidemia             *P*=0.521                                                           
    No                       114 (46.9)      44 (43.1)         /                 /               /
    Yes                      129 (53.1)      58 (56.9)         /                 /               /
  Blood Glucose              *P*=0.747       8.20 ± 4.14       8.53 ± 5.10       0.538           
    Normal                   80 (33.8)       32 (31.7)                                           
    High                     156 (65.8)      69 (68.3)                                           
    Low                      1 (0.4)         0 (0)                                               
  Total cholesterol          *P*=0.719       4.43 ± 1.19       4.55 ± 1.21       0.385           
    Normal                   178 (77.4)      71 (75.5)                                           
    High                     52 (22.6)       23 (24.5)                                           
  Triacylglyceride           *P*=0.373       1.90 ± 1.58       2.29 ± 2.58       0.168           
    Normal                   193 (83.9)      75 (79.8)                                           
    High                     37 (16.1)       19 (20.2)                                           
  High-density lipoprotein   *P*=0.846       0.99 ± 0.27       0.98 ± 0.29       0.708           
    Normal                   105 (45.7)      46 (48.9)                                           
    High                     2 (0.9)         1 (1.1)                                             
    Low                      123 (53.5)      47 (50.0)                                           
  Low-density lipoprotein    *P*=0.510       2.94 ± 1.05       2.91 ± 0.84       0.795           
    Normal                   174 (75.7)      70 (74.5)                                           
    High                     44 (19.1)       16 (17.0)                                           
    Low                      12 (5.2)        8 (8.5)                                             
  Urea nitrogen              *P*=0.980       6.27 ± 3.47       6.44 ± 5.18       0.732           
    Normal                   213 (89.1)      91 (89.2)                                           
    High                     26 (10.9)       11 (10.8)                                           
  Creatinine                 *P*=0.497       89.93 ± 50.92     88.80 ± 31.66     0.835           
    Normal                   227 (95.0)      95 (93.1)                                           
    High                     12 (5.0)        7 (6.9)                                             
  Uric acid                  ***P*=0.014**   359.35 ± 109.90   327.06 ± 115.38   **0.015**       
    Normal                   190 (79.2)      92 (90.2)                                           
    High                     50 (20.8)       10 (9.8)                                            
  Coronary artery lesions    *P*=0.307                                                           
    One                      57 (27.9)       19 (21.3)         /                 /               /
    Two                      39 (19.1)       23 (25.8)         /                 /               /
    Three or more            108 (52.9)      47 (52.8)         /                 /               /
  Gensini score                                                54.30 ± 36.03     50.98 ± 31.89   0.458
  **MALAT1 rs619586**                                                                            
  Smoking                    *P*=0.192                                                           
    No                       88 (30.0)       20 (39.2)         /                 /               /
    Yes                      205 (70.0)      31 (60.8)         /                 /               /
  Drinking                   *P*=0.866                                                           
    No                       215 (73.4)      38 (74.5)         /                 /               /
    Yes                      78 (26.6)       13 (25.5)         /                 /               /
  HBP                        *P*=0.569                                                           
    No                       127 (43.5)      20 (39.2)         /                 /               /
    Yes                      165 (56.5)      31 (60.8)         /                 /               /
  Diabetes                   *P*=0.169                                                           
    No                       222 (75.8)      34 (66.7)         /                 /               /
    Yes                      71 (24.2)       17 (33.3)         /                 /               /
  Cerebrovascular disease    *P*=0.077                                                           
    No                       256 (87.7)      40 (78.4)         /                 /               /
    Yes                      36 (12.3)       11 (21.6)         /                 /               /
  Hyperlipidemia             *P*=0.434                                                           
    No                       138 (47.1)      21 (41.2)         /                 /               /
    Yes                      155 (52.9)      30 (58.8)         /                 /               /
  Blood glucose              *P*=0.169       8.06 ± 3.80       9.10 ± 6.60       0.282           
    Normal                   90 (31.5)       20 (40.0)                                           
    High                     195 (68.2)      29 (58.0)                                           
    Low                      1 (0.3)         1 (2.0)                                             
  Total cholesterol          *P*=0.619       4.49 ± 1.14       4.49 ± 1.56       0.965           
    Normal                   208 (75.4)      37 (78.7)                                           
    High                     68 (24.6)       10 (21.3)                                           
  Triacylglyceride           ***P*=0.003**   1.82 ± 1.39       3.12 ± 3.58       **0.017**       
    Normal                   236 (85.5)      32 (68.1)                                           
    High                     40 (14.5)       15 (31.9)                                           
  High-density lipoprotein   *P*=0.150       1.02 ± 0.29       0.92 ± 0.24       **0.032**       
    Normal                   136 (49.3)      17 (36.2)                                           
    High                     4 (1.4)         0 (0)                                               
    Low                      136 (49.3)      30 (63.8)                                           
  Low-density lipoprotein    *P*=0.572       2.97 ± 1.00       2.75 ± 1.08       0.159           
    Normal                   204 (73.9)      36 (76.6)                                           
    High                     56 (20.3)       7 (14.9)                                            
    Low                      16 (5.8)        4 (8.5)                                             
  Urea nitrogen              *P*=0.077       6.22 ± 3.68       6.84 ± 5.81       0.316           
    Normal                   261 (90.6)      42 (82.4)                                           
    High                     27 (9.4)        9 (17.6)                                            
  Creatinine                 *P*=0.451       90.11 ± 48.60     87.03 ± 29.51     0.662           
    Normal                   273 (94.8)      47 (92.2)                                           
    High                     15 (5.2)        4 (7.8)                                             
  Uric acid                  *P*=0.952       342.75 ± 101.42   385.04 ± 159.87   **0.013**       
    Normal                   239 (82.7)      42 (82.4)                                           
    High                     50 (17.3)       9 (17.6)                                            
  Coronary artery lesions    *P*=0.535                                                           
    One                      66 (26.7)       14 (31.1)         /                 /               /
    Two                      49 (19.8)       11 (24.4)         /                 /               /
    Three or more            132 (53.4)      20 (44.4)         /                 /               /
  Gensini score                                                52.54 ± 33.26     54.48 ± 39.14   0.727

Discussion {#sec4}
==========

In our research, we found the GC genotype and the recessive model of rs4102217 polymorphism showed stronger relations with higher CAD risk both in non-drinkers and in DM history groups. In SNP--SNP interactions analysis between MALAT1 and CAD risk, MALAT1 rs4102217 polymorphism-smoking-drinking had a higher CAD risk. We also found that uric acid was higher in MALAT1 rs4102217 CC+GC genotype. Moreover, the wild-type of triacylglyceride for MALAT1 rs619586 was lower than the mutation-type. There were dramatic increases in uric acid and HDL in the wild-type than in the mutation-type.

MALAT1 is located on chromosome 11q13.1, and its length is 8.1 kb. MALAT-1 is a real non-coding RNA. Due to the lack of enough ORF and the location of its nucleus, the lncRNA cannot encode protein. In recent years, association between lncRNA, MALAT1, and cardiovascular diseases are popular \[[@B20],[@B27]\]. Previous study showed that MALAT1 expression in atherosclerotic plaques was down-regulated and negatively related to age when compared with non-atherosclerotic artery specimens from CAD patients \[[@B30]\]. Another research found that peripheral matrix rather than the cell origin in CAD determined the classification of arterial and coronary vascular smooth muscle. The peripheral matrix lncRNA MALAT1 was sensitive in the peripheral matrix and can regulate the proliferation and migration of arterial and coronary vascular smooth muscle \[[@B31]\]. Thus, above evidences suggested that MALAT1 might be closely related to the development of CAD.

Rs4102217 is a variant of G/C in the exon region of *MALAT1* gene, which has not been reported yet. In our data, we found that there was no relationship in main effect analysis. However, in stratified analysis, the GC genotype and the recessive model of rs4102217 polymorphism showed stronger relations with higher CAD risk both in non-drinkers and in DM history groups. It could be used as a genetic locus to predict CAD risk. Rs619586 is the mutation of nucleotides A/G in the promoter region. Zhou et al. found that MALAT1 rs619586A/G is closely related to pulmonary hypertension risk \[[@B19]\]. Compared with the A loci causing PAH, the G genotype carrier has a lower risk. Another study pointed out that the rs619586 A/G mutation can directly up-regulate the expression of XBP1, and ultimately prevent the proliferation and metastasis of vascular endothelial cells \[[@B19]\]. Report from Wang et al. \[[@B20]\] suggested that rs619586 AG/GG genotypes and G allele were associated with a reduced risk of CAD. Li et al. \[[@B28]\] demonstrated that the functional MALAT1 polymorphism rs619586 A/G was significantly associated with CHD susceptibility in Chinese population. However, we did not find any association with CAD risk in rs619586 in main effect analysis. While, we obtained significant results in further interaction analysis of SNP--SNP and SNP--environment.

CAD is a complex disease involving multiple genes, multiple factors, such as age, sex, smoking, drinking, blood lipids, diabetes, and hypertension \[[@B32]\]. The development of CAD can not only be explained by SNPs. We conducted logistic regression analysis and MDR software analysis respectively to investigate the association between the SNP--SNP or SNP--environment interaction effects of MALAT1 and CAD risk \[[@B24],[@B31],[@B33],[@B34]\]. Our data indicated that MALAT1 rs4102217 interacted with smokers and drinkers. MALAT1 rs619586 AA genotype and GG+AG genotype showed an elevated risk of CAD in smokers. AA genotype and GG+AG genotype showed a reduced risk of CAD in drinkers. To further investigate the relationship, MDR software was used to calculate the best prediction model and the prediction error of the training samples was measured by the test sample (the rest of the sample), while the evaluation for the size of the cross-validation consistency was used. We found that the three factors model, MALAT1 rs4102217 polymorphism-smoking-drinking was the most predictive model for the CAD risk, which had the maximum test accuracy and the maximum cross-validation consistency amongst the analysis results. They indicated that SNP--environment interaction effects were better to predict CAD than SNP alone.

In our research, we also analyzed the relationship between the polymorphism and clinical features. MALAT1 rs4102217 wild-type had more likely to suffer higher uric acid both qualitatively and quantitatively. For MALAT1 rs619586, we found the wild-type genotype carriers had more likely in high triglyceride and low high-density lipoprotein. Moreover, we used the numbers of coronary artery and Gensini score to assess coronary severity in our study. However, we did not find any differences.

Our research indicated that MALAT1 may be associated with the incidence of CAD, but currently, the mechanism of MALAT1 in CAD risk is not yet clear. MALAT1 probably performs its functions in two ways: alternative splicing or gene transcription regulation \[[@B35]\]. Lamond and Spector \[[@B38]\] found that MALAT-1 regulates the expression of post-transcriptional genes by regulating the distribution of SR (serine/arginine-rich) proteins which are rich in the nuclear spots. Moreover, MALAT-1 regulates the pre-mRNA (precursor messenger) level of SR protein. Weiner et al. \[[@B39]\] found that MALAT-1 alternatively regulates splicing by SR protein, including SRSF1, SRSF2, and SRSF3. Knocking down MALAT-1 will lead to ectopic of various splicing factors such as SF1, U2AF65, and SF3a60 \[[@B39]\]. Overexpression of SRSF1 results in alternative splicing results, which is similar to those obtained by knocking down MALAT1.

In summary, our study demonstrated that the polymorphisms (rs4102217, rs619586) of MALAT1 were associated with the CAD risk in Chinese population, which might predict CAD risk in the future.

Limitations {#sec5}
===========

Several limitations remained in our study: first, the sample size was relatively not sufficiently large in our study. The populations selected in our research were all Han people in Liaoning province. So the results of our study need to be validated in larger samples, other regions, and ethnic groups. Second, we only selected two sites of MALAT1. We need to test more sites to verify the association of CAD and MALAT1.
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